Maximilian Merz, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn:
“Honored and thrilled to share that our study was awarded Most Cited Article in HemaSphere Journal 2025!
Our international, multicenter real-world analysis directly compared idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma revealing distinct efficacy, safety, and CAR T-cell kinetics.
Work we hope will help guide treatment decisions for our patients.
This award belongs to every co-author and collaborating center across Germany, Spain, and Switzerland.
Thank you all!
Anca-Maria Albici, Bastian von Tresckow, Kristin Rathje, Roland Fenk, Tobias Holderried, Fabian Muellerüller, Natalia Tovar, Aina Oliver Caldés, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Friedrich Stölzel, Nathalie Schub, Dr. med. Friederike Schmitz, David Fandrei, Patrick Born, Prof. Dr. med. Cyrus Khandanpour, MD, MBA, Christine Hanoun, Keven Hörster, PhD, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Carlos Fernandez de Larrea, Thomas Pabst, Nico Gagelmann.
The picture on the right shows HemaSphere Journal Editor-in-Chief Jan Cools presenting the award to brother Nico, who accepted it on behalf of all authors.”
Title: Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Authors: Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, Kristin Rathje, Roland Fenk, Tobias Holderried, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Friedrich Stölzel, Nathalie Schub, Friederike Schmitz, David Fandrei, Patrick Born, Cyrus Khandanpour, Christine Hanoun, Keven Hörster, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Carlos Fernández de Larrea, Thomas Pabst, Nico Gagelmann
Other articles featuring Maximilian Merz on OncoDaily.
